Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Phase
3Span
333 weeksSponsor
European Organisation for Research and Treatment of Cancer - EORTCGuastalla
Recruiting
1-1 of 1